Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

In ENDEAVOR, carfilzomib (56 mg/m(2)) and dexamethasone (Kd56) demonstrated longer progression-free survival (PFS) over bortezomib and dexamethasone (Vd) in patients with relapsed/refractory multiple myeloma (RRMM). Here we evaluated Kd56 vs Vd by baseline renal function in a post hoc exploratory su...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood
Main Authors: Dimopoulos, Meletios, Siegel, David, White, Darrell J., Boccia, Ralph, Iskander, Karim S., Yang, Zhao, Kimball, Amy S., Mezzi, Khalid, Ludwig, Heinz, Niesvizky, Ruben
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6346374/
https://ncbi.nlm.nih.gov/pubmed/30478094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-06-860015
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares